Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

NCT04675294 is registered in ClinicalTrials.gov with ALX Oncology Inc. as lead sponsor.

NCT NCT04675294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04675294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
Lead sponsor
ALX Oncology Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 2, 2021
Completion date
June 30, 2026
Enrollment
189 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell carcinoma